Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks (RCBs) for three additional preclinical candidates for the potential treatments of B-cell malignan...
Industry Experts to Provide Strategic Guidance as the Companies Advance Technologies Used in the Discovery, Analytics and Manufacturing of Difficult-to-Express Biologics
CrownBio will market a set of new, highly characterized breast cancer models alongside their industry leading collection of more than 2500 PDX models (HuPrime®).
13 of 24
Receive JSR Life Sciences news on your RSS reader.